AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: https://hdl.handle.net/11055/1358
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDowns, Catherineen_US
dc.contributor.authorMarneros, Priscillaen_US
dc.contributor.authorSaxena, Akshaten_US
dc.date2025-08-09en_US
dc.date.accessioned2025-08-26T01:30:11Z-
dc.date.available2025-08-26T01:30:11Z-
dc.identifier.urihttps://hdl.handle.net/11055/1358-
dc.description.abstractBACKGROUND: Dual antiplatelet therapy (DAPT) significantly reduces mortality and recurrent events in patients with acute coronary syndromes. However, patients requiring coronary artery bypass grafting (CABG) face an increased bleeding risk due to DAPT, leading to a conventional “washout” period of up to seven days before surgery. This waiting period extends hospital stay and contributes to higher healthcare costs. Importantly, up to 50% of patients exhibit no significant platelet inhibition during this time. Platelet function testing using the Multiplate analyser may allow for earlier surgery in patients whose platelet function has recovered, potentially reducing hospital stay and associated costs. We propose a prospective randomized controlled trial to evaluate the safety, efficacy, and cost-effectiveness of this approach. AIM: We aim to determine whether early CABG, guided by Multiplate platelet function testing, is non-inferior to conventional delayed surgery in terms of postoperative bleeding and transfusion requirements. We hypothesise that Multiplate-guided surgery does not increase bleeding risk and results in comparable or improved healthcare outcomes. STUDY DESIGN: Two parallel studies are proposed. 1. Randomised Controlled Trial (RCT): Eligible patients will be randomized to either early surgery (treatment group) or standard care (control group) after meeting predefined Multiplate criteria. 2. Prospective Observational Study: Patients who do not qualify for the RCT but undergo either early or delayed surgery will be followed for data collection to support broader health economic analysis. ELIGIBILITY CRITERIA: Participants must: • Require CABG following recent use of clopidogrel, ticagrelor, or prasugrel. • Be within the traditional antiplatelet washout window. • Meet Multiplate criteria indicating sufficient platelet recovery for surgery. MEASUREMENTS AND OUTCOMES DEFINITIONS: Primary outcome: Chest drain output at 24 hours postoperatively, indexed to blood volume (Nadler equation). • Secondary outcomes: Red cell and platelet transfusion requirements, quality of life (EQ5DL) at baseline and 6 months, surgery and discharge dates, readmission, and mortality. • Multiplate testing: ADP and TRAP pathway results compared to an established algortihm. Aspirin response documented but not used for eligibility. • Additional data: Patient weight and height (for blood volume), and timepoint relative to last antiplatelet dose. SAMPLE SIZE CALCULATION: Based on retrospective data for the control group, the coefficients of variation of both groups are assumed to be 0.500. Group sample sizes of 107 in the first group and 107 in the second group achieve 80% power to detect non-inferiority using a one-sided, two-sample t-test. The margin of non-inferiority is 0.200. The true ratio of the means at which the power is evaluated is 1.000. The significance level (alpha) of the test is 0.025. FEASIBILITY: Given that approximately 50% of CABG patients are on DAPT and half meet the Multiplate eligibility threshold, we estimate each site could recruit 25 patients annually. A multicentre effort involving 6 hospitals performing 200–400 CABG procedures annually could achieve recruitment targets within three years (Assuming a quarter of potential patients make it from initial assessment to study completion). COLLABORATION: We are in discussions with Prof. Jason Abbott (UNSW) a colleague with a good track record for academic collaboration. Engagement with the Multiplate supplier (Haemoview) and ANZSCTS is underway. Ethics approvals at institutional and national levels are being pursued, with planned registration through ANZCTR. SPECIFIC ISSUES FOR DISCUSSION: 1. Is a single 6-month quality-of-life follow-up sufficient? 2. What is the most effective pathway for multi-centre approval, funding, and recruitment? 3. What local and central resources are required, including budgeting for personnel and data management?en_US
dc.subjectMultiplate platelet functionen_US
dc.subjectCardiac Surgeryen_US
dc.subjectSafetyen_US
dc.subjectCost effectivenessen_US
dc.titleProposed RCT using a Multiplace platelet function algorithm to expedite urgent cardiac surgery and determine safety and cost effectiveness.en_US
dc.typeConference Paperen_US
dc.type.contentTexten_US
dc.description.conferencenameANZCA Clinical Trials Networken_US
dc.description.affiliatesPrince of Wales Hospitalen_US
dc.description.affiliatesUniversity of New South Walesen_US
dc.description.conferencelocationAdelaideen_US
dc.type.studyortrialRandomized Controlled Clinical Trial/Controlled Clinical Trialen_US
dc.ispartof.anzcaresearchfoundationYesen_US
dc.identifier.anzcaeventYesen_US
dc.type.specialtyAnaesthesiaen_US
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeConference Paper-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
Appears in Collections:Scholarly and Clinical
Files in This Item:
File Description SizeFormat 
Downs_CTN abstracts_2025_August_FINAL.pdfABSTRACT PDF320.79 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

164
checked on May 23, 2026

Download(s)

72
checked on May 23, 2026

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.